Elite Pharma Inc
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral do… Read more
Elite Pharma Inc (ELTP) - Net Assets
Latest net assets as of September 2025: $61.58 Million USD
Based on the latest financial reports, Elite Pharma Inc (ELTP) has net assets worth $61.58 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($117.25 Million) and total liabilities ($55.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $61.58 Million |
| % of Total Assets | 52.53% |
| Annual Growth Rate | 12.02% |
| 5-Year Change | 231.32% |
| 10-Year Change | 379.38% |
| Growth Volatility | 94.09 |
Elite Pharma Inc - Net Assets Trend (1999–2025)
This chart illustrates how Elite Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Elite Pharma Inc (1999–2025)
The table below shows the annual net assets of Elite Pharma Inc from 1999 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $53.52 Million | -7.06% |
| 2024-03-31 | $57.58 Million | +98.83% |
| 2023-03-31 | $28.96 Million | +14.82% |
| 2022-03-31 | $25.22 Million | +56.15% |
| 2021-03-31 | $16.15 Million | +51.58% |
| 2020-03-31 | $10.66 Million | -6.50% |
| 2019-03-31 | $11.40 Million | -38.32% |
| 2018-03-31 | $18.48 Million | -28.01% |
| 2017-03-31 | $25.66 Million | +129.89% |
| 2016-03-31 | $11.16 Million | +132.14% |
| 2015-03-31 | $-34.73 Million | +57.23% |
| 2014-03-31 | $-81.20 Million | -836.18% |
| 2013-03-31 | $-8.67 Million | +42.11% |
| 2012-03-31 | $-14.98 Million | +16.16% |
| 2011-03-31 | $-17.87 Million | -68.63% |
| 2010-03-31 | $-10.60 Million | -278.32% |
| 2009-03-31 | $5.94 Million | -43.66% |
| 2008-03-31 | $10.55 Million | +200.50% |
| 2007-03-31 | $3.51 Million | -64.08% |
| 2006-03-31 | $9.77 Million | +71.40% |
| 2005-03-31 | $5.70 Million | +40.86% |
| 2004-03-31 | $4.05 Million | -25.40% |
| 2003-03-31 | $5.43 Million | -33.45% |
| 2002-03-31 | $8.15 Million | -11.18% |
| 2001-03-31 | $9.18 Million | +64.98% |
| 2000-03-31 | $5.56 Million | +98.74% |
| 1999-03-31 | $2.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Elite Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11660392600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $174.22 Million | 325.55% |
| Total Equity | $53.52 Million | 100.00% |
Elite Pharma Inc Competitors by Market Cap
The table below lists competitors of Elite Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CJ CGV
KO:079160
|
$265.70 Million |
|
Godrej Agrovet Limited
NSE:GODREJAGRO
|
$265.74 Million |
|
Wisesoft Co Ltd
SHE:002253
|
$265.79 Million |
|
Bumi Serpong Damai Tbk
JK:BSDE
|
$265.81 Million |
|
IVU Traffic Technologies AG
PINK:IVUFF
|
$265.55 Million |
|
Ampoc Far-East Co Ltd
TW:2493
|
$265.52 Million |
|
Formosa Sumco Technology Corp
TW:3532
|
$265.50 Million |
|
Grupo Rotoplas S.A.B. de C.V
PINK:GRPRF
|
$265.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Elite Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 57,582,818 to 53,515,029, a change of -4,067,789 (-7.1%).
- Net loss of 4,314,659 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.31 Million | -8.06% |
| Other Changes | $246.87K | +0.46% |
| Total Change | $- | -7.06% |
Book Value vs Market Value Analysis
This analysis compares Elite Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.84x to 6.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-03-31 | $0.38 | $0.32 | x |
| 2000-03-31 | $0.67 | $0.32 | x |
| 2001-03-31 | $1.00 | $0.32 | x |
| 2002-03-31 | $0.85 | $0.32 | x |
| 2003-03-31 | $0.54 | $0.32 | x |
| 2004-03-31 | $0.36 | $0.32 | x |
| 2005-03-31 | $0.44 | $0.32 | x |
| 2006-03-31 | $0.53 | $0.32 | x |
| 2007-03-31 | $0.18 | $0.32 | x |
| 2008-03-31 | $0.48 | $0.32 | x |
| 2009-03-31 | $0.19 | $0.32 | x |
| 2010-03-31 | $-0.14 | $0.32 | x |
| 2011-03-31 | $-0.18 | $0.32 | x |
| 2012-03-31 | $-0.06 | $0.32 | x |
| 2013-03-31 | $-0.02 | $0.32 | x |
| 2014-03-31 | $-0.18 | $0.32 | x |
| 2015-03-31 | $-0.05 | $0.32 | x |
| 2016-03-31 | $0.02 | $0.32 | x |
| 2017-03-31 | $0.03 | $0.32 | x |
| 2018-03-31 | $0.02 | $0.32 | x |
| 2019-03-31 | $0.01 | $0.32 | x |
| 2020-03-31 | $0.01 | $0.32 | x |
| 2021-03-31 | $0.02 | $0.32 | x |
| 2022-03-31 | $0.02 | $0.32 | x |
| 2023-03-31 | $0.03 | $0.32 | x |
| 2024-03-31 | $0.05 | $0.32 | x |
| 2025-03-31 | $0.05 | $0.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Elite Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.13%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.80x
- Recent ROE (-8.06%) is below the historical average (515.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -60.71% | -850.00% | 0.06x | 1.11x | $-1.98 Million |
| 2000 | -53.49% | -28854.99% | 0.00x | 1.65x | $-3.53 Million |
| 2001 | -152.12% | -14662.01% | 0.01x | 1.35x | $-14.88 Million |
| 2002 | -21.76% | -148.19% | 0.09x | 1.56x | $-2.59 Million |
| 2003 | -74.84% | -644.35% | 0.07x | 1.60x | $-4.60 Million |
| 2004 | -160.92% | -2522.45% | 0.03x | 1.94x | $-6.92 Million |
| 2005 | -103.59% | -1959.30% | 0.03x | 1.62x | $-6.48 Million |
| 2006 | -70.43% | -1250.04% | 0.04x | 1.61x | $-7.86 Million |
| 2007 | -336.23% | -1031.92% | 0.12x | 2.76x | $-12.15 Million |
| 2008 | -131.70% | -983.15% | 0.09x | 1.45x | $-14.95 Million |
| 2009 | -111.13% | -290.34% | 0.21x | 1.84x | $-7.20 Million |
| 2010 | 0.00% | -240.91% | 0.32x | 0.00x | $-7.00 Million |
| 2011 | 0.00% | -318.38% | 0.36x | 0.00x | $-11.80 Million |
| 2012 | 0.00% | -621.19% | 0.24x | 0.00x | $-13.56 Million |
| 2013 | 0.00% | 43.72% | 0.31x | 0.00x | $2.36 Million |
| 2014 | 0.00% | -2098.83% | 0.19x | 0.00x | $-88.46 Million |
| 2015 | 0.00% | 576.83% | 0.19x | 0.00x | $32.40 Million |
| 2016 | -6.12% | -5.46% | 0.39x | 2.86x | $-1.80 Million |
| 2017 | 14.85% | 39.54% | 0.28x | 1.34x | $1.24 Million |
| 2018 | -19.88% | -49.25% | 0.24x | 1.67x | $-5.52 Million |
| 2019 | -81.43% | -122.60% | 0.31x | 2.14x | $-10.42 Million |
| 2020 | -21.02% | -12.45% | 0.72x | 2.34x | $-3.31 Million |
| 2021 | 31.50% | 20.05% | 0.97x | 1.62x | $3.47 Million |
| 2022 | 35.28% | 27.58% | 0.92x | 1.39x | $6.38 Million |
| 2023 | 15227.43% | 12.91% | 835.17x | 1.41x | $4.41 Billion |
| 2024 | 34.92% | 35.51% | 0.68x | 1.45x | $14.35 Million |
| 2025 | -8.06% | -5.13% | 0.87x | 1.80x | $-9.67 Million |
Industry Comparison
This section compares Elite Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Elite Pharma Inc (ELTP) | $61.58 Million | -60.71% | 0.90x | $265.56 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |